Thursday, 20 June, 2019, 5:12 PM
Home Health & Nutrition

Health Research

A new oral antibiotic treats gonorrhea

Published : Friday, 11 January, 2019 at 12:00 AM  Count : 949
Abu Saim Mohammad Saikat

Gonorrhea is a sexually transmitted infection (STI), one of the most common diseases in Bangladesh. It is caused by infection with the bacterium Neisseria gonorrhoeae.
Men may have burning with urination, discharge from the penis, or testicular pain.Women may have burn with urination, vaginal discharge, vaginal bleeding between periods, or pelvic pain. Complications in women include pelvic inflammatory disease and in men include inflammation of the epididymis.If untreated, gonorrhea can spread to joints or heart valves, and an increased risk of HIV infection.
Gonorrhea is spread through unprotected oral, anal, or vaginal sex. People with numerous sexual partners or those who don't use a condom are at greatest risk of infection. The best protection against infection is abstinence, monogamy (sex with only one partner), and proper condom usage. Currently gonorrhea is treated with an antibiotic injection of Ceftriaxone one time to the buttocks or a single dose of Azithromycin by mouth.
As the incidence of gonorrhea continues to rise and Neisseria gonorrhoeae develops resistance to more antibiotics, a new Phase II trial reveals that zoliflodacin (ETX0914) successfully treated most uncomplicated urogenital and rectal gonococcal infections. WHO has warned that widespread gonorrhea treatment failure could be on the horizon if new drugs aren't developed.
Zoliflodacin acts on the DNA synthesis, inhibiting it in a different way than current antibiotics. Men and women who had signs or symptoms of uncomplicated urogenital gonorrhea or untreated urogenital gonorrhea, a single oral dose of zoliflodacin 2 g or 3 gis needed for the treatment of gonorrhea that is comparable with a single 500mg intramuscular dose of ceftriaxone (randomized 7:7:4) was conducted at five sites in the USA.
The US FDA (Food and Drug Administration) has awarded fast-track status to zoliflodacin for the development as an oral treatment to gonococcal infections. The drug is due to being Phase III trial running year.

The writer is a student of BSMRSTU



« PreviousNext »



Latest News
Most Read News
Editor : Iqbal Sobhan Chowdhury
Published by the Editor on behalf of the Observer Ltd. from Globe Printers, 24/A, New Eskaton Road, Ramna, Dhaka.
Editorial, News and Commercial Offices : Aziz Bhaban (2nd floor), 93, Motijheel C/A, Dhaka-1000. Phone :9586651-58. Online: 9513959, Advertisement: 9513663
E-mail: info@dailyobserverbd.com, online@dailyobserverbd.com, news@dailyobserverbd.com, advertisement@dailyobserverbd.com,   [ABOUT US]     [CONTACT US]   [AD RATE]   Developed & Maintenance by i2soft